Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 11/20 | 0.37 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902662 | 0.90 | PRKAB2 (0.33) | MAPKAPK2CRHR1KCNN3HTR2ASLC6A4 | |
| SCHEMBL902492 | 0.90 | CRHR1 (0.38) | CRHR1KCNN3 | |
| SCHEMBL902348 | 0.77 | MAPT (0.43) | KCNN3 | |
| SCHEMBL902696 | 0.77 | MAPKAPK2 (0.40) | MAPKAPK2CDK2CRHR1KCNN3PDE4A | |
| SCHEMBL902416 | 0.75 | HSP90AA1 (0.39) | CRHR1 | |
| SCHEMBL902798 | 0.74 | PDE4B (0.36) | CRHR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL902392 | 0.74 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL902365 | 0.72 | NPBWR1 (0.44) | CRHR1KCNN3HTR2ASLC6A4KCNH2 | |
| SCHEMBL902317 | 0.72 | PDE4A (0.47) | CRHR1PDE4A | |
| SCHEMBL902806 | 0.70 | NPBWR1 (0.40) | CRHR1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| EP-2621928-A1 | 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | Proximagen Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041817-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | CCR2, CCR5, CCR1 | MAPKAPK2 1066/4885CDK2 184/4885CRHR1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.